The invention discloses crystal form I of a deuterium labelled imidazolone compound (4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl}-2-fluoro-N-three deuterated methyl benzamide) and preparation and use thereof. The present crystal form I is a stable crystal form, and has well reproducibility and stability in storage, significantly better than the existing amorphous substance as well as newly discovered crystal form II, such that quality of an active pharmaceutical ingredient of 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl}-2-fluoro-N-three deuterated methyl benzamide is stable in a storage period. Meanwhile, the present crystal form I has a simple preparation method, low cost and broad market prospects.本發明揭露了一種氘代咪唑酮-4-{3-[4-氰基-3-(三氟甲基)苯基]-5,5-二甲基-4-氧代-2-硫代-1-咪唑烷基}-2-氟-N-三氘代甲基苯醯胺化合物的晶型I及其製備方法和用途。本發明的晶型I，晶型穩定，重現性好，放置穩定，顯著優於現有的無定形物以及新發現的晶型Ⅱ，使得4-{3-[4-氰基-3-(三氟甲基)苯基]-5,5-二甲基-4-氧代-2-硫代-1-咪唑烷基}-2-氟-N-三氘代甲基苯醯胺原料藥在存儲期內品質更穩定。同時，本發明的晶型I，製備方法簡單，成本低，具有廣闊的市場前景。
